ArticleClinical and experimental rheumatology2023

Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al.

Emine Duran et al.PubMed ↗Publisher ↗

No numbers read from the abstract.